ABSTRACT
BACKGROUND: Cutaneous viral infections and immune suppression are risk factors for some forms of nonmelanoma skin cancer; however, their interrelationship is poorly understood. OBJECTIVES: To examine cross-sectional associations between cutaneous viral infections and circulating forkhead-box P3 (FOXP3)-expressing T-regulatory (Treg) cells, suppressive cells that dampen effective antitumour immunity. MATERIALS AND METHODS: Blood, eyebrow hair (EBH) and skin swab (SSW) samples were collected from 352 patients 60 years and older undergoing skin screening, without prevalent skin cancer, while participating in an ongoing prospective cohort study of cutaneous viral infections and skin cancer. DNA corresponding to 98 cutaneous human papillomavirus (HPV) types and five human polyomaviruses (HPyV) was assessed in EBH and SSW. Distinct classes of circulating Treg-cell subpopulations were defined by flow cytometry including cutaneous lymphocyte antigen (CLA) and CCR4high Treg cells, both previously associated with cutaneous diseases. Age- and sex-adjusted associations between circulating T-cell populations and infection were estimated using logistic regression. RESULTS: Total Treg-cell proportion in peripheral blood was not associated with ß HPV or HPyV infection. However, the proportion of circulating CLA+ Treg cells was inversely associated with γ HPV EBH infection [odds ratio (OR) 0·54, 95% confidence interval (CI) 0·35-0·84]. Interestingly, circulating Treg cells expressing markers indicative of antigen activation (CD27- CD45RA- FOXP3+ CD4+ ) were also inversely associated with γ HPV infection in SSW (OR 0·55, 95% CI 0·30-0·99) and EBH (OR 0·56, 95% CI 0·36-0·86). CONCLUSIONS: Inverse associations between circulating Treg cells and γ HPV infection suggest that localized viral infection may promote immunosuppressive cell migration into skin.
Subject(s)
Gammapapillomavirus/isolation & purification , Immune Tolerance , Papillomavirus Infections/immunology , Skin Diseases, Viral/immunology , T-Lymphocytes, Regulatory/immunology , Aged , Carcinogenesis/immunology , Cross-Sectional Studies , DNA, Viral/isolation & purification , Eyebrows/immunology , Eyebrows/virology , Female , Gammapapillomavirus/genetics , Gammapapillomavirus/immunology , Humans , Male , Middle Aged , Papillomavirus Infections/blood , Papillomavirus Infections/virology , Polyomavirus/genetics , Polyomavirus/immunology , Polyomavirus/isolation & purification , Polyomavirus Infections/blood , Polyomavirus Infections/immunology , Polyomavirus Infections/virology , Prospective Studies , Skin/immunology , Skin/virology , Skin Diseases, Viral/blood , Skin Diseases, Viral/virology , Skin Neoplasms/immunology , Tumor Virus Infections/blood , Tumor Virus Infections/immunology , Tumor Virus Infections/virologyABSTRACT
The high-risk Alpha-types of human papillomavirus (HPV) are the causative agent of cervical cancer, which is the second major cause of death among women worldwide. Recent investigations have shown that E7 from the Alpha-papillomavirus HPV-16 interacts with IKKα and IKKß of the IKK complex in the NF-κB pathway leading to an attenuation of the activity. There is a possible link between development of non-melanoma skin cancer and cutaneous Beta-papillomavirus but if these HPV types attenuate the NF-κB pathway is unclear. Seven different E7 proteins, representing four out of the five different species of the Beta genus (HPV-20, -37, -38, -92, -93 and -96) and one from the Gamma genus (HPV-4) were investigated for potential modulation of the NF-κB pathway in U2OS cells. Our results demonstrate that E7 from all the cutaneous HPV types were capable of inhibiting the NF-κB activity as well as E7 from HPV-16. In addition, E7 proteins from the cutaneous HPV types demonstrated interaction with IKKα but not with IKKß. The deregulation of the NF-κB pathway by cutaneous HPVs might contribute to the pathogenesis of non-melanoma skin cancers and its precursors.
Subject(s)
Betapapillomavirus/pathogenicity , Gammapapillomavirus/pathogenicity , I-kappa B Kinase/antagonists & inhibitors , Immune Tolerance , Papillomavirus E7 Proteins/metabolism , Signal Transduction , Betapapillomavirus/immunology , Cell Line , Gammapapillomavirus/immunology , Humans , NF-kappa B/antagonists & inhibitors , Papillomavirus E7 Proteins/immunology , Protein Interaction Mapping , Skin Neoplasms/virologyABSTRACT
Two hundred female sex workers (FSWs) in Lima, Peru were randomized to receive HPV4 vaccine in the standard (0, 2, 6 months) or a modified schedule (0, 3, 6 months). One hundred and eighty four (92%) participants completed 3 doses of vaccine. Baseline seropositive rates were 58% for HPV6, 22.5% for HPV11, 41.5% for HPV16, and 13% for HPV18. The final geometric mean antibody titer (GMT) following vaccination was significantly greater for women who were seropositive at baseline compared to seronegative women: HPV6 (GMT ratio=2.3, p<0.01), HPV11 (GMT ratio=2.7, p<0.01), HPV16 (GMT ratio=1.3, p=0.04), and HPV18 (GMT ratio=2.4, p<0.01). Antibody titers in the modified schedule were not inferior to those in the standard schedule, suggesting the modified schedule may be paired with required STD visits. Although all women benefit from vaccination, administration at a younger age and before sexual debut is needed to achieve maximum protection from vaccine.
Subject(s)
Antibodies, Viral/blood , Gammapapillomavirus/immunology , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/immunology , Sex Workers , Adolescent , Adult , Alphapapillomavirus/genetics , Alphapapillomavirus/immunology , Alphapapillomavirus/isolation & purification , Cervix Uteri/virology , Female , Humans , Immunization Schedule , Papillomavirus Infections/epidemiology , Papillomavirus Infections/immunology , Papillomavirus Infections/virology , Papillomavirus Vaccines/administration & dosage , Peru , Treatment Outcome , Vaccination , Young AdultABSTRACT
BACKGROUND: Adolescent HPV vaccination in minority and low income populations with high cervical cancer incidence and mortality could reduce disparities. Safety-net primary care clinics are a key delivery site for improving vaccination rates in these populations. PURPOSE: To examine prevalence of HPV initiation (≥ 1 dose), completion (receipt of dose 3 within 12 months of initiation), and receipt of 3 doses in four safety-net clinics as well as individual-, household-, and clinic-level correlates of initiation. METHODS: We used multilevel modeling to investigate HPV initiation among 700 adolescent females who sought primary care in four safety-net clinics in Dallas, Texas from March 2007 to December 2009. Data were abstracted from patients' paper and electronic medical records. RESULTS: HPV vaccine uptake varied significantly by clinic. Across clinics, initiation was 36.6% and completion was 39.7% among those who initiated. In the total study population, only 15.7% received all three doses. In multivariate, two-level logistic regression analyses, initiation was associated with receipt of other adolescent vaccines, influenza vaccination in the year prior to data abstraction, being sexually active, and having more chart documentation (presence of health maintenance questionnaire and/or immunization record). There was no association between initiation and age, race/ethnicity, or insurance status. CONCLUSIONS: In four urban safety-net clinics, HPV initiation rates paralleled 2008 national rates. The correlation of HPV initiation with other adolescent vaccines underscores the importance of reviewing vaccination status at every health care visit. HPV vaccine uptake in safety-net clinics should continue to be monitored to understand impact on cervical cancer disparities.
Subject(s)
Ambulatory Care Facilities/statistics & numerical data , Immunization Programs/statistics & numerical data , Papillomavirus Vaccines/administration & dosage , Urban Population , Vaccination/statistics & numerical data , Adolescent , Child , Family Characteristics , Female , Gammapapillomavirus/immunology , Healthcare Disparities , Humans , Papillomavirus Infections/epidemiology , Papillomavirus Infections/prevention & control , Papillomavirus Infections/virology , Papillomavirus Vaccines/immunology , Primary Health Care , Texas , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/virologySubject(s)
Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/therapeutic use , Adolescent , Adult , Child , Gammapapillomavirus/drug effects , Gammapapillomavirus/immunology , Health Services Accessibility , Humans , Male , Men's Health , Papillomavirus Infections/immunology , Papillomavirus Vaccines/immunology , Young AdultABSTRACT
HPV4 is now available for boys, and a second vaccine to protect against HPV-associated cancer has been approved. Should you be using these vaccines in your practice?
Subject(s)
Papillomavirus Infections/prevention & control , Papillomavirus Vaccines , Adolescent , Adult , Anus Neoplasms/epidemiology , Anus Neoplasms/prevention & control , Anus Neoplasms/virology , Attitude of Health Personnel , Centers for Disease Control and Prevention, U.S. , Child , Female , Gammapapillomavirus/immunology , Humans , Male , Papillomavirus Infections/complications , Papillomavirus Vaccines/adverse effects , Safety , Societies, Medical , United States , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/prevention & control , Uterine Cervical Neoplasms/virology , Vaccination , World Health Organization , Young AdultABSTRACT
OBJECTIVE: To examine the rate and correlates of completion of the quadrivalent human papillomavirus vaccine (HPV4) 3-dose regimen because nonadherence to the regimen may adversely affect vaccine efficacy. PARTICIPANTS AND METHODS: Female members of Kaiser Permanente Southern California who were 9 to 26 years old, received the first dose of HPV4 between October 2006 and March 2007, and maintained health plan membership 12 months afterward were identified and followed up for regimen completion. We examined the following: (1) demographics/socioeconomic status, (2) primary care physician characteristics, (3) historical health service utilization, (4) women's health-related conditions, and (5) selected immune-related conditions for their association with completion in 2 age groups: 9 to 17 years and 18 to 26 years. Multivariable log-binomial regression was used to directly estimate relative risk (RR). RESULTS: Of the 34,193 females who initiated HPV4, the completion rate was 41.9% in the 9- to 17-year-old group and 47.1% in the 18- to 26-year-old group. Black race (RR, 0.70; 95% confidence interval [CI], 0.64-0.77) and lower neighborhood education level were associated with lower regimen completion. However, those in the 9- to 17-year-old group who were covered by the state-subsidized program Medi-Cal were more likely to complete the regimen (RR, 1.14; 95% CI, 1.07-1.22). Historical hospitalizations and emergency department visits (RR, 0.92; 95% CI, 0.87-0.96; and RR, 0.96; 95% CI, 0.94-0.98 per visit, respectively) and having a pediatrician were also predictors of noncompletion. A history of sexually transmitted diseases, abnormal Papanicolaou test results, and immune-related conditions (eg, asthma/infections) were not associated with regimen completion. CONCLUSION: These findings suggest that factors such as race or socioeconomic status should be considered when human papillomavirus vaccination programs are being designed and evaluated.